Latest News and Press Releases

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based...

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT...

FDA grants Orphan Drug Designation to Medicovestor’s ADoBind MC001, a novel ADC targeting hard-to-treat pancreatic cancer.

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Interim analysis shows misetionamide is very well tolerated in combination with gemcitabine; rates of confirmed response, stable disease, and progression-free survival compare favorably with...

PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around...

Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Oncology Collaboration and Licensing Deals 2020-2025" report has been added to ResearchAndMarkets.com's offering.Oncology Collaboration and Licensing...

These results indicate that EXACT Therapeutics’ Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapyIn the patients who had a response to chemotherapy, ACT-treated...